Literature DB >> 10598694

Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment.

D Fortin1, G J Cairncross, R R Hammond.   

Abstract

OBJECTIVE: This article reviews and summarizes recent data on the diagnosis, prognosis, and treatment of oligodendroglial tumors.
METHODS: Histological criteria for optimized diagnosis and grading of oligodendroglial tumors are described and discussed. The therapeutic approaches are analyzed in light of the results of recent series.
RESULTS: Oligodendroglial tumors may be more common than is generally thought. Perinuclear halo and "chicken-wire" pattern, although considered classic histological features of oligodendrogliomas, are unreliable as sole criteria for diagnosis. Nuclear regularity and roundness and an eccentric rim of eosinophilic cytoplasm lacking obvious cell processes are more constant features. Grading should be accomplished using a composite of radiological and histopathological relevant features. The allelic loss of chromosome arms 1p and 19q might be a marker for both chemosensitivity and longer survival after chemotherapy. Oligodendrogliomas are notably chemosensitive when compared with other gliomas. For aggressive lesions, chemotherapy should be used upfront, after surgery.
CONCLUSION: Oligodendrogliomas are underdiagnosed. One unfortunate implication is that a large number of patients may be receiving suboptimal care. A simplification in grading of oligodendroglioma to two grades would reduce the confusion surrounding the classification and better define prognosis and response to treatment modalities. A better definition of the so-called mixed tumor should also allow a better classification of these lesions in an intermediate prognostic class between astrocytic and oligodendroglial lesions. Loss of 1p and 19q could be used as a cytogenetic marker in assisting grading. New concepts emerging in the recent literature should help optimize the diagnosis of these lesions and reduce interobserver variability.

Entities:  

Mesh:

Year:  1999        PMID: 10598694     DOI: 10.1097/00006123-199912000-00001

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  36 in total

1.  The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases.

Authors:  A Korshunov; A Golanov
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  The presence of necrosis and/or microvascular proliferation does not influence survival of patients with anaplastic oligodendroglial tumours: review of 98 patients.

Authors:  Sarah F Smith; Judy M Simpson; Janice A Brewer; Lali H S Sekhon; Michael T Biggs; Raymond J Cook; Nicholas S Little
Journal:  J Neurooncol       Date:  2006-06-23       Impact factor: 4.130

3.  Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas?

Authors:  Matthew L White; Yan Zhang; Patricia Kirby; Timothy C Ryken
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

Review 4.  Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium.

Authors:  Melissa L Bondy; Michael E Scheurer; Beatrice Malmer; Jill S Barnholtz-Sloan; Faith G Davis; Dora Il'yasova; Carol Kruchko; Bridget J McCarthy; Preetha Rajaraman; Judith A Schwartzbaum; Siegal Sadetzki; Brigitte Schlehofer; Tarik Tihan; Joseph L Wiemels; Margaret Wrensch; Patricia A Buffler
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

5.  Antioxidant enzymes in oligodendroglial brain tumors: association with proliferation, apoptotic activity and survival.

Authors:  Sally Järvelä; Järvelä Sally; Helena Bragge; Bragge Helena; Niina Paunu; Paunu Niina; Timo Järvelä; Järvelä Timo; Leo Paljärvi; Paljärvi Leo; Hannu Kalimo; Kalimo Hannu; Pauli Helén; Helén Pauli; Vuokko Kinnula; Kinnula Vuokko; Ylermi Soini; Soini Ylermi; Hannu Haapasalo; Haapasalo Hannu
Journal:  J Neurooncol       Date:  2006-04       Impact factor: 4.130

6.  Imaging characteristics of oligodendrogliomas that predict grade.

Authors:  L Khalid; M Carone; N Dumrongpisutikul; J Intrapiromkul; D Bonekamp; P B Barker; D M Yousem
Journal:  AJNR Am J Neuroradiol       Date:  2012-01-19       Impact factor: 3.825

7.  Supratentorial low-grade glioma resectability: statistical predictive analysis based on anatomic MR features and tumor characteristics.

Authors:  Ion-Florin Talos; Kelly H Zou; Lucila Ohno-Machado; Jui G Bhagwat; Ron Kikinis; Peter M Black; Ferenc A Jolesz
Journal:  Radiology       Date:  2006-05       Impact factor: 11.105

8.  FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading.

Authors:  Gabriele Pöpperl; Friedrich W Kreth; Jan H Mehrkens; Jochen Herms; Klaus Seelos; Walter Koch; Franz J Gildehaus; Hans A Kretzschmar; Jörg C Tonn; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-01       Impact factor: 9.236

9.  Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens.

Authors:  Raymond I Haroun; Richard E Clatterbuck; M Christopher Gibbons; Peter C Burger; Ricardo Parker; John P Fruehauf; Henry Brem
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

Review 10.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.